GILD · News · 20261112N
HIV and PrEP Demand Growth
GILEAD SCIENCES, INC. · 2026-11-12 · Importance 38 · Surprise 24
Biktarvy held more than 53% of the U.S. HIV treatment market. Descovy sales were driven primarily by higher demand and average realized price, with PrEP accounting for approximately 80% of Descovy sales. Gilead’s PrEP portfolio includes daily oral Descovy and twice-yearly injectable Yeztugo, which provided incremental contributions to the HIV business. The article also cites strong Biktarvy and Descovy performance but gives no dollar sales or growth rates for these products.
Key facts
- Gilead Sciences announced a new collaboration with TelevisaUnivision and the 27th Latin GRAMMY Awards to bring HIV prevention awareness to Latino audiences. source
- Descovy performance was driven primarily by higher demand and average realized price, and PrEP sales accounted for approximately 80% of total Descovy sales. source
- Gilead Sciences' HIV PrEP portfolio comprises daily oral Descovy and twice-yearly injectable Yeztugo. source